Literature DB >> 4085525

Theoretical Michaelis-Menten elimination model for propranolol.

J McAinsh, M A Gay.   

Abstract

A pharmacokinetic model, with Michaelis-Menten elimination, has been developed for drugs and propranolol in particular. The theory is given and the relationship between the area under the theoretical plasma level curve and the absorption rate constant is discussed. This approach allows for an explanation of many of the observed pharmacokinetics of 'Inderal' and particularly 'Inderal' LA; a sustained release preparation of propranolol. In particular, the bioavailability, as measured by area under the curve, is found to be strongly dependent on the absorption half-life in agreement with experimentally observed data.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4085525     DOI: 10.1007/BF03189748

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  10 in total

1.  Studies of the absorption and removal of propranolol in hypertensive patients during therapy.

Authors:  C A Chidsey; P Morselli; G Bianchetti; A Morganti; G Leonetti; A Zanchetti
Journal:  Circulation       Date:  1975-08       Impact factor: 29.690

2.  The disposition of propranolol. 3. Decreased half-life and volume of distribution as a result of plasma binding in man, monkey, dog and rat.

Authors:  G H Evans; A S Nies; D G Shand
Journal:  J Pharmacol Exp Ther       Date:  1973-07       Impact factor: 4.030

3.  Propranolol in hypertension: a study of long-term therapy, 1964-1970.

Authors:  F J Zacharias; K J Cowen; J Prestt; J Vickers; B G Wall
Journal:  Am Heart J       Date:  1972-06       Impact factor: 4.749

4.  To be taken as directed.

Authors:  M S Gatley
Journal:  J R Coll Gen Pract       Date:  1968-07

5.  The dropout problem in antihypertensive treatment. A pilot study of social and emotional factors influencing a patient's ability to follow antihypertensive treatment.

Authors:  J R Caldwell; S Cobb; M D Dowling; D de Jongh
Journal:  J Chronic Dis       Date:  1970-02

6.  Pharmacokinetic and pharmacodynamic studies with long-acting propranolol.

Authors:  J McAinsh; N S Baber; R Smith; J Young
Journal:  Br J Clin Pharmacol       Date:  1978-08       Impact factor: 4.335

7.  Propranolol given twice daily in hypertension.

Authors:  G Berglund; O Andersson; L Hansson; R Olander
Journal:  Acta Med Scand       Date:  1973-12

8.  Influence of the route of administration on the mean hepatic extraction ratio of propranolol in the rat.

Authors:  T Suzuki; S Isozaki; T Ohkuma; T Rikihisa
Journal:  J Pharmacobiodyn       Date:  1980-11

9.  Nonlinear first-pass metabolism of propranolol in the rat.

Authors:  T Suzuki; T Ohkuma; S Isozaki
Journal:  J Pharmacobiodyn       Date:  1981-02

10.  Bioavailability of sustained release propranolol formulations.

Authors:  J McAinsh; N S Baber; B F Holmes; J Young; S H Ellis
Journal:  Biopharm Drug Dispos       Date:  1981 Jan-Mar       Impact factor: 1.627

  10 in total
  4 in total

Review 1.  Nonlinear pharmacokinetics: clinical Implications.

Authors:  T M Ludden
Journal:  Clin Pharmacokinet       Date:  1991-06       Impact factor: 6.447

Review 2.  Clinical significance of pharmacokinetic models of hepatic elimination.

Authors:  D J Morgan; R A Smallwood
Journal:  Clin Pharmacokinet       Date:  1990-01       Impact factor: 6.447

3.  Flavone acetic acid: a nonlinear pharmacokinetic model.

Authors:  A Gouyette; D J Kerr; S B Kaye; A Setanoians; J Cassidy; C Bradley; G Forrest; M Soukop
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

4.  Propranolol inhalation challenge in relation to histamine response in children with asthma.

Authors:  J Gerritsen; G H Koëter; L T Vander Weele; K Knol
Journal:  Thorax       Date:  1988-06       Impact factor: 9.139

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.